Artiva Biotherapeutics, Inc. (ARTV)
NasdaqGM · USD · Healthcare · Biotechnology
$6.16 (+0.16%) as of
Key statistics
- Market cap
- 301.16M
- Forward P/E
- -2.36
- EPS (TTM)
- -3.23
- Dividend yield
- 0.00%
- 52-week range
- 2.96 – 14.53
- Beta
- 2.41
- Profit margin
- 0.00%
- Analyst target
- $35.80
- Volume
- 487.01k
About Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- San Diego, CA, United States
- Employees
- 115
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.